Cancer Research

Applications (S)-5-tert-Butoxy-4-(3-((s)-1,5-di-tert-butoxy-1,5-dioxopentan-2-yl)ureido)-5-oxopentanoic Acid is used as a reactant in the synthesis of a DUPA-paclitaxel conjugate for antigen targeted therapy of prostate cancer.
References Lv, Qingzhi, et al.: Mol. Pharma., 15(5), 1842-1852 (2018)

Impurity Irinotecan USP Related Compound E
Applications An anticancer drug, showed strong activity against various murine tumors. A Camptothecin (CPT) derivative as antineoplastic agent against drug-resistant tumors. Irinotecan USP Related Compound E.
References Brangi, M., et al.: Cancer Res., 59 5938 (1999), Miyake, K., et al.: Cancer Res., 59, 8 (1999) , Bom, D., et al.: J. Med. Chem., 43, 3970 (2000) , Gamcsik, M., et al.: Mol. Cancer Ther., 1, 11 (2001).

Stability Light Sensitive
Applications β-Cembrenediol is an inhibitor of tumor promotion. Novel c-Met inhibitors which are used in anticancer treatments.
References Le-Huu, P. et al.: ChemCatChem., 8, 3755 (2016); Ebrahim, H. et al.: Bioorg. Med. Chem., 24, 5748 (2016);

Applications Principal pigment of bile and constituent of many biliary calculi.
References Stenhagen, R., et al.: Biochem. J., 33, 1591 (1939), Gray, et al.: J. Chem. Soc., 2264, 2268 (1961),

Applications Withanolide A, is a neuritogenic steroid. It may act as deterrent for feeding insect larva and other herbivores. Withaferin A, causes activation of Notch2 and Notch4 in human breast cancer cells, and thus used as novel anticancer agents.
References Liffert, R., et al.: Chemical Science, 4, 2851 (2013); Lee. J., et al.: Breast Cancer, Res. treat., 136, 45 (2012);

Stability Reacts with DMSO
Applications A metabolite of Cyclophosphamide (C988580).
Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package
References Bohnenstengel, F., et al.: Eur. J. Clin. Pharmacol., 51, 297 (1996), Busse, D., et al.: J. Clin. Oncol., 15, 188 (1997), Roy, P., et al.: Drug Metab. Dispos., 27, 655 (1999),

Applications (2R,3S)-N-Benzoyl-3-phenyl Isoserine Methyl Ester is an intermediate in the preparation of potent anticancer drug Paclitaxel (P132500) used to study the location of the binding sites.
References Paal, K. et al.: Bioorg. Med. Chem., 15, 1323 (2007); Krawczyk, E. et al.: J. Pharm. Pharmacol., 57, 791 (2005);

Impurity Anastrozole Monoamide Impurity
Applications Anastrozole Monoamide is a derivative of Anastrozole (A637425), an aromatase inhibitor. Used as an antineoplastic.
References Plourde, P.V., et al.: Breast Cancer Res. Treat., 30, 103 (1994), Buzdar, A.U., et al.: Cancer, 79, 730 (1997)

Applications cis-Etoposide is an anticancer agent that has half-life of 2 days at pH 7.4 and 37° resulting in the loss of 90% of the active drug within 1 week during in vitro incubations.
References Mader, R. M., et al.: Cancer Chemotherapy and Pharmacol., 27, 354 (1991)

Applications Melphalan is an antineoplastic.
Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package
References Ross, W.C.J., et al.: Biochem. Pharmacol., 13, 969 (1964); Donelli, M.G., et al.: J. Pharm. Pharmacol., 18, 760 (1966), Furner, R.L., et al.: Cancer Treat. Rep., 64, 559 (1980),

Applications Labelled Dodecyl Phthalate (D525380). Dodecyl Phthalate is used in the preparation of Cytarabine (C998100) derivatives as anticancer agents.
References Aoshima, M., et al.: Cancer Res., 36, 2726 (1976), Wang, N., et al.: Bioorg. Med. Chem. Lett., 15, 4064 (2005), Marie-Helene, G., et al.: Bioorg. Med. Chem., 2009, 17, 6340 (2009),

Applications A coordination compound for treatment of cervix cancer.
References Jiang, M., et al.: Methods Mol. Biol., 292, 401 (2005), Fujii, T., et al.: Int. J. Oncol., 29, 541 (2006), Niu, X., et al.: Int. J. Gynecol. Cancer, 16, 743 (2006),

Applications N-Demethyl-3-methoxy-4-hydroxytamoxifen is an metabolite of Tamoxifen (T006000), a selective estrogen response modifier (SERM), protein kinase C inhibitor and anti-angiogenetic factor.
References Zhang, F., et al.: Chem. Rs. Toxicol., 13, 53 (2000); Sutherland, R., et al.: Nature, 267, 434 (1977); Lerner, L., et al.: Cancer Res., 50, 4177 (1990); Love, R., et al.: J. Clin. Oncol., 20 2559 (2002)